4.6 Article

LATE-NC staging in routine neuropathologic diagnosis: an update

Journal

ACTA NEUROPATHOLOGICA
Volume -, Issue -, Pages -

Publisher

SPRINGER
DOI: 10.1007/s00401-022-02524-2

Keywords

Dementia; Processes; NCI; TDP-43; FTD; Stages; Hippocampal sclerosis; Neuroanatomy; Aging

Funding

  1. National Institutes of Health
  2. California Department Of Public Health [P30 AG072958, P30 AG072977, K08 AG065463, RF1 AG072080, K08 AG 065426, R01 AG038651, UF1 AG057707, R01 AG021055, P30 AG066519 (UCI ADRC), R01 AG061111, R01 AG057187, P30 AG072946, RF1 NS118584, P01 AG066597, P30 AG072979, U19 AG062418, P30 AG072959, R01 AG062706, R01 AG054449, R01 AG075802, P30 AG 066507, U19 AG033655, RF1 AG069052, P30 AG072972, U19 AG069701, K24 AG053435, R01 AG067482, R01 AG064233, P30 AG010161/P30 AG072975, U01 AG061357, R01AG052132, R01 AG056519, R01 AG062517, R01 AG022018]
  3. 2019 California Budget Act [19-10611]
  4. Academy of Finland [P30 AG072958, P30 AG072977, K08 AG065463, RF1 AG072080, K08 AG 065426, R01 AG038651, UF1 AG057707, R01 AG021055, P30 AG066519 (UCI ADRC), R01 AG061111, R01 AG057187]
  5. State funding for university-level health research [P30 AG072946]
  6. Liv och Haelsa Foundation [RF1 NS118584, P01 AG066597]
  7. Rossy Foundation
  8. Edmond Safra Philanthropic Foundation
  9. NOMIS foundation and Alzheimer Forschung Initiative
  10. UK Medical Research Council (MRC) [P30 AG072979, U19 AG062418]
  11. Addenbrooke's Charitable Trust [P30 AG072959, R01 AG062706, R01 AG054449]
  12. Paul G. Allen Foundation [R01 AG075802]
  13. ARUK NSG
  14. Alzheimer's Society
  15. Nancy and Buster Alvord Endowment [K08 AG 065426, P30 AG 066507]
  16. National Institute for Health Research, Cambridge Biomedical Research Centre
  17. Fonds Wetenschappelijk Onder-zoek Vlaanderen [P30 AG072958]
  18. Stichting Alzheimer Onderzoek Belgie [P30 AG072977, K08 AG065463]
  19. KU-Leuven Internal Funds (Belgium) [RF1 AG072080]
  20. BrightFocus Foundation [P30 AG072958]
  21. Miguel Servet program [P30 AG072977]
  22. Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) [K08 AG065463]
  23. Society for the Promotion of Research in Experimental Neurology, Vienna, Austria//Alzheimer's Research UK (ARUK) [RF1 AG072080]
  24. AMED [R01 AG038651]
  25. [K23 AG062750]
  26. [U19 AG024904]
  27. [R21 AG078538]
  28. [P30 AG 010133]
  29. [P30 AG062677]
  30. [P30 AG066512]
  31. [UF1 NS125417]
  32. [U01 AG006786]
  33. [R01 AG034676]
  34. [P30 AG066509]
  35. [U19 AG066567]
  36. [341007]
  37. [TYH2020231]
  38. [TYH2022316]
  39. [21004]
  40. [13803]
  41. [MRC/G9901400]
  42. [U.1052.00.0013]
  43. [G0900582]
  44. [900108]
  45. [554 (AS-PG-2019b-024)]
  46. [AS-JF-18-01]
  47. [UK ARUK-PhD2014-19]
  48. [FWO: G0F8516N]
  49. [G065721N]
  50. [SAO-FRA: 2020/017]
  51. [C14/17/107]
  52. [C14/22/132]
  53. [C3/20/057]
  54. [PDMT2/21/069]
  55. [A2022019F]
  56. [CP19/00031]
  57. [PI20/00613]
  58. [ARUK-PhD2017-34]
  59. [JP22wm0425019]

Ask authors/readers for more resources

This report updates the neuropathologic criteria for diagnosing and staging LATE-NC and provides practical suggestions for integrating genetic information and comorbid pathologies. It also highlights recent research findings that improve differentiation of LATE-NC from other subtypes of TDP-43 pathology and offers guidance for diagnosing unusual cases. Additionally, the report describes the neuroanatomical regions of interest in LATE-NC and specifies the implications for TDP-43 immunohistochemical results. The report emphasizes unresolved questions and areas requiring further study.
An international consensus report in 2019 recommended a classification system for limbic-predominant age-related TDP-43 encephalopathy neuropathologic changes (LATE-NC). The suggested neuropathologic staging system and nomenclature have proven useful for autopsy practice and dementia research. However, some issues remain unresolved, such as cases with unusual features that do not fit with current diagnostic categories. The goal of this report is to update the neuropathologic criteria for the diagnosis and staging of LATE-NC, based primarily on published data. We provide practical suggestions about how to integrate available genetic information and comorbid pathologies [e.g., Alzheimer's disease neuropathologic changes (ADNC) and Lewy body disease]. We also describe recent research findings that have enabled more precise guidance on how to differentiate LATE-NC from other subtypes of TDP-43 pathology [e.g., frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS)], and how to render diagnoses in unusual situations in which TDP-43 pathology does not follow the staging scheme proposed in 2019. Specific recommendations are also made on when not to apply this diagnostic term based on current knowledge. Neuroanatomical regions of interest in LATE-NC are described in detail and the implications for TDP-43 immunohistochemical results are specified more precisely. We also highlight questions that remain unresolved and areas needing additional study. In summary, the current work lays out a number of recommendations to improve the precision of LATE-NC staging based on published reports and diagnostic experience.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available